The Buzz Surrounding: Todos Medical Ltd. (OTCQB: TOMDF) | Financial Buzz

The Buzz Surrounding: Todos Medical Ltd. (OTCQB: TOMDF)

Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer’s disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc.

Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer’s disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. 

Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared
Analyses), a method for cancer screening using peripheral blood analysis.

The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. 

Our Behind the Buzz Show Featuring Todos Medical Ltd.

Investor Recap

 

April 21, 2020 - Todos Medical Announces US FDA Emergency Use Authorization Allowed for Gnomegen COVID-19 PCR Test Kits

Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, as well as point-of-care and lab-based tests for COVID-19, today announced that Gnomegen LLC (“Gnomegen”) has received Emergency Use Authorization (“EUA”) from the US Food & Drug Administration (FDA) for its real-time digital polymerase chain reaction (RT-Digital PCR Detection) diagnostic test for COVID-19. Gibraltar Brothers & Associates, LLC, a US-based subsidiary of Shanghai Liangrun Biomedicine Technology Co., has added Gnomegen as a supplier of PCR Test Kits to Todos under Gibraltar’s existing agreements with Todos, thereby allowing Todos to use the Gnomegen PCR Test Kits for its CLIA laboratory services business, as well as for distribution through Todos’ network. 

Todos is currently validating Gnomegen’s PCR Test Kits in its partner CLIA lab (Provista) where it is also in validation for automated extraction machines to achieve High Throughput status with Centers for Medicare and Medicaid Services (CMS). On April 15, 2020, CMS increased its payment rates for High-Throughput SARS-CoV-2 diagnostic tests that use high-throughput technologies allowing for increased capacity and faster results to $100 per test. A High-Throughput testing lab can process at least 200 specimens per day using “highly-sophisticated equipment that requires specially trained technicians and more more-intensive processes to assure quality,” according to CMS. Provista expects that it can scale up to a capacity of up to 2,000 PCR diagnostic tests per day in May 2020. Provista intends to offer lab services for customers who utilize a variety sample collection methods, including oropharyngeal, nasopharyngeal, stool and saliva.

“We are very pleased to see Gnomegen’s PCR Test Kits achieve EUA status with the US FDA,” said Gerald Commissiong, President & CEO of Todos. “Gnomegen’s highly sensitive RT Digital PCR test kits are especially promising given the high sensitivity for RT digital PCR. This will be a great addition to our partner 3D Med’s automated extraction machine which allows for significantly increased throughput over traditional lab workflows. We expect to begin offering PCR services in May to qualified customers with a view towards being a lab partner of choice for our antibody test kit customers who need confirmatory results.”

About the SARS-CoV-2 Coronavirus (COVID-19)

Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is the disease caused by SARS-CoV-2.

For Full Release: https://www.globenewswire.com/news-release/2020/04/21/2019383/0/en/Todos-Medical-Announces-US-FDA-Emergency-Use-Authorization-Allowed-for-Gnomegen-COVID-19-PCR-Test-Kits.html

April 17, 2020 - Todos Medical Appoints Dr. Lauren Chung to its Board of Directors

Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders as well as point-of-care and lab-based tests for COVID-19, announces the appointment of Lauren Chung, Ph.D. to its Board of Directors. This appointment increases the size of the Todos Medical Board to 7 Directors, including 2 independent Directors.  Dr. Chung has been named lead independent Director, and will serve as Chair of both the Compensation Committee and the Nomination and Governance Committee.

Todos Medical also announces it has received the independent third-party valuation report required to complete the full acquisition of its joint venture Breakthrough Diagnostics, Inc. that is developing the proprietary immune-based Alzheimer’s disease blood diagnostic LymPro Test. Additionally, the Company announces that it has retained Donohoe Advisors to assist with its proposed listing on the Nasdaq CM™ national stock exchange in the United States.

“I am excited to join Todos at this key time in its growth trajectory,” said Dr. Chung. “With its recent entry into the COVID-19 testing space, Todos has taken a thoughtful, incremental approach to the market by focusing on the underlying biology of the disease as the field’s understanding is evolving, and how this will impact biomarker activation and relationships.  This will help to inform physicians on how to use the tools we will be making available to diagnose, monitor and ultimately evaluate patient response to new therapies as they begin to enter the marketplace.”

She added, “This approach was born out of Todos Medical’s approach to Alzheimer’s disease given the lack of easy-to-use, effective diagnostic tools in that indication. With the enormous impact of COVID-19 and Alzheimer’s disease on the United States economy, Todos grasps the importance of sound science and following the data. I believe this approach will position the Company well for both near- and long-term success, and I look forward to assisting the Company in achieving its objective.”

Dr. Chung is the founder and CEO of MINLEIGH LLC, which is focused on identifying, evaluating and partnering with companies for investments and strategic, operational, and commercial opportunities. She has over 20 years of healthcare investment management, investment banking and advisory experience, and is currently a venture partner at Yozma Group Asia headquartered in South Korea. 

Dr. Chung was a managing director in Healthcare Research at WestPark Capital. Previously, she was a co-founder of Tokum Capital Management, a global healthcare fund, which merged with Perella Weinberg Partners. Prior to that, Dr. Chung managed healthcare investment portfolios at RBR Capital, Kingdon Capital and Pequot Capital. Earlier in her career, Dr. Chung was a research scientist doing cutting-edge work in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital. Dr. Chung has published in many leading peer-reviewed scientific journals. 

As a current and former director of public and private companies, Dr. Chung brings a valuable perspective for the Company’s strategy and operations, as well as extensive scientific insights. Dr. Chung serves on the business review board of the Alzheimer’s Drug Discovery Foundation. Dr. Chung holds a Ph.D. in neuropathology from Columbia University-College of Physicians & Surgeons, and a BA with honors in Biochemistry and Economics from Wellesley College.

“We have been working with Dr. Chung for some time on an informal basis, and she has provided significant insight and guidance on positioning the Company for future growth,” said Gerald E. Commissiong, President & CEO of Todos Medical. “We believe Alzheimer’s disease is effectively cancer of post-mitotic neurons, and this is the basis for aligning Todos’ cancer platform with the LymPro Alzheimer’s platform. Given Dr. Chung’s extensive background in the scientific and business communities in the Alzheimer’s space, and broad reach into the Asian capital markets, now is the time to bring Lauren on board as we build the Company’s profile as a leader in immune-based diagnostics for cancer, Alzheimer’s disease and COVID-19 in preparation for national stock exchange listing.”

For Full Release: https://www.globenewswire.com/news-release/2020/04/17/2017937/0/en/Todos-Medical-Appoints-Dr-Lauren-Chung-to-its-Board-of-Directors.html

April 15, 2020 - Todos Medical Achieves Medical Importer Status with US FDA

Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that the United States Food & Drug Administration has accepted Todos Medical’s application for Medical Device Establishment Registration. This designation allows Todos to import medical devices for commercial sale that have been manufactured by non-US entities. Todos has entered into agreements to import point-of-care (POC) antibody fingerprick blood-based testing kits (Ab POC Testing Kits) and COVID-19 digital PCR-based testing kits from oral/nasopharyngeal swabs, saliva and stool (PCR Testing Kits), as well as automated extraction laboratory equipment (Automated Extraction) to support a newly established risk stratification screening and reflex high throughput diagnostic testing paradigm that it believes will allow for greater access to highly accurate testing in the United States. Todos intends to distribute Ab PCR Testing Kits to medical providers, pharmacies and government entities throughout the United States, and market PCR Testing Kits and Automated Extraction to CLIA/CAP-certified labs in the United States in addition to running PCR Testing Kits using Automated Extraction in its partner CLIA/CAP-certified lab. 

About the SARS-CoV-2 Coronavirus (COVID-19)

Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is the disease caused by SARS-CoV-2.

For Full Release: https://www.globenewswire.com/news-release/2020/04/15/2016435/0/en/Todos-Medical-Achieves-Medical-Importer-Status-with-US-FDA.html

March 30, 2020 - Todos Medical Expands on Coronavirus (COVID-19) Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar

Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has expanded its exclusive distribution agreement (the “Distribution Agreement”) with Gibraltar Brothers & Associates, LLC, a US-based subsidiary of Shanghai Liangrun Biomedicine Technology Co., to include polymerase chain reaction (PCR) testing kits in addition to colloidal gold IgM/IgG immunochromatography antibody test (“Colloidal Gold”). Todos will be commercializing the PCR kits Colloidal Gold through Corona Diagnostics, LLC, its COVID-19 focused joint venture with Emerald Organic Products, Inc. (OTC: EMOR).

Additionally, the jurisdictions to which Todos was granted exclusive rights by Gibraltar was expanded beyond the United States and Israel, and now also includes Singapore, Malaysia, Indonesia, Thailand, Myanmar, Vietnam, Philippines, Cambodia/Laos, Hong Kong, Japan, South Korea, Taiwan, India, United Kingdom, Sweden, Italy, India, Gulf States, Dubai and UAE. Dr. Joseph Wee, CEO of Todos’ subsidiary Todos Medical Singapore Pte Ltd., will be responsible for the commercialization effort in Asia.

“I am very pleased to lead the effort to bring point-of-care and additional PCR antibody testing to the Asian market,” said Dr. Joseph Wee, CEO of Todos Medical Singapore Ltd. “Adding this important assay to the standard paradigm for screening and diagnosis for COVID-19 will help us triage patients at point-of-care, identify those patients who have previously been infected by COVID, and more easily monitor the natural course of the disease in general.”

COLLOIDAL GOLD NOVEL CORONAVIRUS (COVID-19) TEST KIT VIDEO INSTRUCTIONS

VIDEO LINK: https://www.youtube.com/watch?v=bqkqUkZljFs&feature=youtu.be 

A point of care test kit uses a drop of blood from a finger prick to test for antibodies to COVID-19.  The test kit contains a detection kit, the lancet, the disinfectant wipe, micropipette, cotton ball, and the reagent.  The kit comes in a sealed plastic bag and also contains instructions.  The only thing not included is the timer.  This is a rapid test that takes between 2 to 10 minutes versus the nasal swab currently in widespread use that takes up to 72 hours or more for results.  

For Full Release: https://www.globenewswire.com/news-release/2020/03/30/2008409/0/en/Todos-Medical-Expands-on-Coronavirus-COVID-19-Distribution-Agreement-with-Shanghai-Liangrun-Subsidiary-Gibraltar.html

March 19, 2020 - Todos Medical Signs Novel Coronavirus (COVID-19) Point-of-Care Rapid Antibody Testing Kit Exclusive Distribution Agreement for the United States and Israel with Shanghai Liangrun Subsidiary Gibraltar

Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced it has entered into an exclusive distribution agreement for the United States and Israel (the “Distribution Agreement”) with Gibraltar Brothers & Associates, LLC, a U.S.-based subsidiary of Shanghai Liangrun Biomedicine Technology Co. (“Shanghai”), for its proprietary colloidal gold immunochromatography test (“Colloidal Gold”). 

Colloidal Gold has been approved as a diagnostic test for the novel coronavirus (COVID-19) in China by the NMPA (formerly the China FDA) and in Europe under a CE Mark. Todos will be responsible for obtaining U.S. Food and Drug Administration (FDA) approval and plans to do so under the Emergency Use Authorization Program. 

Shanghai has shipped test kits for validation by Todos. During the four-week validation process, Todos intends to place its first purchase order based upon the market demand identified. Shanghai currently has 500,000 Colloidal Gold test kits in stock, and has indicated to Todos that it can manufacture up to 300,000 test kits per day to help meet the demand in the U.S., given that demand for test kits in China has begun to decline.

COLLOIDAL GOLD NOVEL CORONAVIRUS (COVID-19) TEST KIT VIDEO INSTRUCTIONS

VIDEO LINK: https://www.youtube.com/watch?v=bqkqUkZljFs&feature=youtu.be 

The Colloidal Gold point-of-care (POC) test kit uses a drop of blood from a finger prick to test for antibodies to COVID-19.  The test kit contains a detection kit, a lancet, a disinfectant wipe, a micropipette, a cotton ball and the reagent.  The kit comes in a sealed plastic bag and includes instructions; the only thing not included is a timer.  This is a rapid test that takes between two and 10 minutes to obtain results, compared with the nasal swab test currently in widespread use that takes two to three days for results.  

“I’m pleased to see Todos take on the task of bringing additional COVID-19 testing capacity into the United States, where we expect significant demand in the coming months as we grapple with the international pandemic,” said Jorge Leon, Ph.D., Chief Medical Advisor to Todos. “The IgM antibody response to the SARS-CoV-2 virus appears at days 5-6 after infection showing recent exposure to the virus, and lasts for up to three weeks, therefore it is an important test to increase the window of diagnostic sensitivity of true positive cases since the molecular test (nucleic acid test), despite being the gold standard,  is not always positive in some patients during the early course of infection. The IgG antibody response peaks at day 21 and lasts for years, indicating the patient was infected with the virus. The Colloidal Gold IgM/IgG tests has become a very important test in the coronavirus testing paradigm, and we will be working to validate the assay here in the United States in the coming weeks in preparation for commercial launch under CLIA and parallel interactions with U.S. federal authorities to expedite its path to FDA approval using the recently enacted Emergency Use Authorization Program. Because Colloidal Gold tests for antibodies to the virus that causes COVID-19 (SARS-CoV-2), instead of testing for the virus itself, this test will be different and complementary to the nucleic acid test Todos will be validating in parallel. Validating and making available the Colloidal Gold and lab-based molecular testing together or in parallel has the potential to create a new paradigm in the screening for COVID-19 that we believe may allow for EUA from US FDA for Colloidal Gold POC test kit.”

Todos and Provista Diagnostics, Inc. have agreed to use Provista’s lab in Alpharetta, Georgia to conduct the validation required to launch the test in the U.S. under CLIA. Todos entered into an exclusive option to acquire Provista, and this transaction is expected to close in the second quarter of 2020. All COVID-19 testing inquiries should be directed via email to covidtesting@provistadx.com. 

Rao Mulpuri, Ph.D., Chief Operating Officer of Provista, commented, “We are very pleased to help validate and ultimately offer this new, more comprehensive testing paradigm to meet the needs of our country during this COVID-19 crisis.”  

“In these extraordinary times, the value of widespread medical testing has become clearer than ever.  We are proud to use our business development expertise to identify multiple solutions that together have the potential to significantly increase testing accuracy and capacity in the U.S. by screening large numbers of patients in places where traditional lab testing methods may not be able to meet the demand,” said Gerald Commissiong, President & CEO of Todos Medical. 

“The concept behind a rapid test is to triage and quarantine the patient as quickly as possible after detection,” he added.  “This test can be done at a doctor’s office or in a clinic by a nurse practitioner, but we are particularly focused on nursing homes and senior care centers.  These locations typically house seniors with underlying medical conditions that make them the most at-risk population due to lack of mobility.  Through testing we believe communities can quickly identify infections earlier and limit a group’s overall exposure to COVID-19, which is particularly deadly in this demographic. There are more than 65 million Americans over the age of 65, and this is one of the most at-risk populations for whom we must ensure early detection. We also are looking to ensure solutions for various government organizations, self-insured employers, small businesses as well as other groups who need access to testing.”

Clinical Results from Clinical Trial in Wuhan, China

All samples were tested using the Colloidal Gold diagnostic device, and the results were compared to RT-PCR or clinical diagnosis (including chest Computed Tomography and clinical signs and symptoms) of Novel Coronavirus. Colloidal Gold was evaluated with 188 blood samples obtained from clinically confirmed COVID-19 patients from multiple Chinese Hospitals and the Chinese CDC laboratories (positive), as well as 182 non-SARS-CoV-2 infected patients (negative). The results were:

  •  Sensitivity (positive): 90.43% (170/182)
  •  Specificity (negative): 100% (182/182) 

For Full Release: https://www.globenewswire.com/news-release/2020/03/19/2003290/0/en/Todos-Medical-Signs-Novel-Coronavirus-COVID-19-Point-of-Care-Rapid-Antibody-Testing-Kit-Exclusive-Distribution-Agreement-for-the-United-States-and-Israel-with-Shanghai-Liangrun-Sub.html

March 17, 2020 - Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel

Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has entered into a non-exclusive distribution agreement with 3DMedicine Science & Technology Co (3DMed), a China-based cancer precision medicine company, for distribution in the US and Israel of 3DMed’s ANDiS® SARS-CoV-2 Detection Kit (COVID), ANDiS® SARS-CoV-2  & Influenza A/B Detection Kit (COVID/Flu) and its proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). 3DMed’s COVID, COVID/Flu and 3D Machine have received a CE Mark in Europe. 3D Machine also has received approval from the Chinese FDA. 3DMed is currently engaged in discussions with the FDA regarding approval of its products.

“I am very pleased to help Todos and 3DMed bring this technology forward for commercial launch in the US under CLIA, and help support FDA approval for 3DMed’s suite of products here in the United States as quickly as possible,” said Jorge Leon, PhD, Chief Medical Advisor to Todos. “The main differentiation in the 3DMed offering vs. other nucleic acid PCR-based testing is the influenza A and B tests combined with coronavirus testing. This is a clinically meaningful combination because of the extended flu season in the United States that will create additional doubt among healthcare providers regarding the cause of symptoms for patients. The fact that this will be available in one testing paradigm seems to be novel in the United States.”

Concurrent with this announcement, Todos and Provista Diagnostics, Inc. have agreed to use Provista’s lab in Alpharetta, Georgia to conduct the CLIA validation required to launch the test in the United States. All inquiries should be directed via email to covidtesting@provistadx.com. Rao Mulpuri, PhD, MBA Chief Operating Officer of Provista, commented, “Todos Medical and Provista Diagnostics will work together to complete the validation and make the product available to healthcare providers in a timely manner.”

3D BioMed has shipped materials to the Provista lab in Georgia in order to support the validation being conducted over the coming weeks.

“PCR is the current gold standard for diagnosing novel coronavirus in the United States and abroad,” said Gerald Commissiong, President & CEO of Todos. “We believe 3DMed’s ANDiS® 350 and kits provide some of the best results in the market because of the engineering applied in establishing the automation that reduces variability and human error in the lab, while increasing throughput. We intend to work expeditiously to validate this technology at Provista, so that we can come online in the US and add additional critically needed testing capacity to the nation’s infrastructure.”

“The 2019-20 coronavirus pandemic becomes an ongoing global pandemic of coronavirus disease. We have got many lessons in coronavirus fighting in Wuhan, China in the past few months and want to share the experiences with the rest of the world. Fully automated viral RNA extraction systems and precise nucleic acid detection kits played critical roles in rapidly diagnosing coronavirus disease 2019 with a large scale in Wuhan, China,” said Simon Shung, President & CEO of 3DMed. “Meanwhile, to distinguish between early symptoms of the flu and coronavirus would become very important since people may feel similar to those suffering from their symptoms. We hope to help the US and other countries stop the coronavirus spreading through the collaboration with Todos by doing more precise nucleic acid tests with our products, which were validated by tons of cases in the past few months.”

“We’re thrilled to work with Todos, a well-recognized innovative Dx company,” said Caifu Chen, Chief Technology Officer of 3DMed. “Two young technology companies share common goals in fighting cancer and now the new global 2019-nCoV epidemic brings us together to stop its spreading by precisely identifying virus infected individuals using highly sensitive and specific proprietary RT-qPCR assays developed at 3DMed. Our past experiences in catching this terrible virus in Wuhan areas will help Todos build high-performance 2019-nCoV test labs in the US in a record time.”

For Full Release: https://www.globenewswire.com/news-release/2020/03/17/2002107/0/en/Todos-Medical-and-3DMed-Enter-Into-Coronavirus-COVID-19-and-Influenza-A-B-Testing-Kit-Distribution-Agreement-in-US-and-Israel.html

March 02, 2020 - Todos Medical Announces Publication Demonstrating Potential of FTIR Platform to Identify Bacterial and Viral Infections

Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced the publication of data from a human clinical study in the scientific journal Analytical Chemistry entitled “Differential Diagnosis of the Etiologies of Bacterial and Viral Infections Using Infrared Microscopy of Peripheral Human Blood Samples and Multivariate Analysis”. The data demonstrate that the use of the Fourier-transform infrared (FTIR) spectroscopy technique on peripheral blood samples yields a differential diagnosis when seeking to make a clinical diagnosis between patients with viral infections, bacterial infections and healthy controls.

“With the recent explosion of novel coronavirus (2019-nCoV) worldwide, definitively diagnosing viral infections versus bacterial or other types of infections that present with similar symptoms has become paramount in order to appropriately triage patients and guide treatment decisions for healthcare professionals,” said Gerald Commissiong, President & CEO of Todos Medical. “Todos’ proprietary FTIR blood testing platform that focuses on the immune system’s reaction to cancer has received CE Marks in Europe for the diagnosis of breast cancer and colon cancer, has recently achieved strong analytical performance results from our proprietary sample preparation methods, and is currently enrolling a pre-commercial breast cancer study in Romania with distribution partner Orot+ (a division of Orot Luces) ahead of an expected commercial launch in Romania later this year. Based on these recent successes and this publication from the Company’s licensors at Ben Gurion University, we have now formally begun to evaluate the commercial feasibility of applying our technology towards the diagnosis of bacterial and viral infections, including coronavirus. Because we use AI to create the algorithms required to differentially diagnosis cancer, we believe the rate limiting step towards creating algorithms for viral and bacterial infections on our platform is access to sufficient viral and bacterial patient samples in order create those new algorithms. As such, we have begun outreach efforts to determine the potential of obtaining such samples from coronavirus-affected jurisdictions.”

For Full Release: https://www.globenewswire.com/news-release/2020/03/02/1993515/0/en/Todos-Medical-Announces-Publication-Demonstrating-Potential-of-FTIR-Platform-to-Identify-Bacterial-and-Viral-Infections.html

Feb. 25, 2020 - Todos Medical Announces Legacy Convertible Note Extension, Lock-Up Agreements, and New Debt Financing

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced it has entered into convertible note extension agreements and lock-up agreements with certain institutional investors who participated in the Company’s previously announced $1.35M financing round in Q1 2019 (the ‘2019 Bridge Financing’). All remaining investors who participated in the 2019 Bridge Financing have agreed to extend the maturity of those notes until mid-August 2020 and have entered into lock-up agreements with the Company that preclude them from selling common shares in the market until mid-August 2020. A new institutional investor purchased $295,000 in convertible notes from certain institutional investors who participated in the 2019 Financing in order to help facilitate the transaction. Concurrently, the Company completed a raise of $163,000 in new convertible debt financing with certain new domestic and Israel-based investors (the ‘2020 Bridge Financing’).

“As Todos is positioning itself to achieve a listing on the Nasdaq Capital Market in the coming months, we believe this series of agreements positions the Company’s capital structure properly to achieve growth as we move into the process,” said Gerald Commissiong, President & CEO of Todos Medical. “Going forward, we are staying focused on the tasks of completing our financial reporting requirements and executing on our clinical, regulatory and commercial initiatives to create value heading into the listing process.”

For Full Release: https://www.globenewswire.com/news-release/2020/02/25/1989998/0/en/Todos-Medical-Announces-Legacy-Convertible-Note-Extension-Lock-Up-Agreements-and-New-Debt-Financing.html

Feb. 19, 2020 - Todos Medical Receives Notice of Allowance from European Patent Office Covering Diagnosis of Solid Tumors Using AI to Analyze Blood

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has received a notice of allowance from the European Patent Office (EPO) covering the use of Todos’ proprietary Total Biochemical Infrared Analysis (TBIA) platform to identify solid tumors using peripheral blood mononuclear cells (PBMCs). The specific claims being granted cover the use of Fourier Transformed Infrared Analysis (FTIR) spectroscopy and using artificial intelligence on the infrared (IR) data obtained to build algorithms based on the IR spectrum that are predictive of the presence of different types of solid tumors with different tissues of origin. The Company expects the patent to be issued in the coming weeks.

“We are very pleased to see the expansion of the Todos intellectual property portfolio in Europe where Todos is currently in the midst of a pre-commercialization study with partner Orot+ (a division of Orot Luces) for our TM-B1 and TM-B2 breast cancer blood tests,” said Gerald E. Commissiong, President & CEO of Todos Medical. “This particular patent is very significant because it covers the method of using TBIA for the identification of solid tumors. The potential of this technology to eventually be used as a broad screening tool for all cancers, given the low costs of goods sold (COGS) to implement the assay, would represent a sea-change in terms of the ability to do broad cancer screenings for health systems.”

For Full Release: https://www.globenewswire.com/news-release/2020/02/19/1986956/0/en/Todos-Medical-Receives-Notice-of-Allowance-from-European-Patent-Office-Covering-Diagnosis-of-Solid-Tumors-Using-AI-to-Analyze-Blood.html

Jan. 09, 2020 - Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has entered into an exclusive option agreement to acquire Provista Diagnostics, Inc., an in vitro diagnostics company with a CLIA/CAP certified lab in Alpharetta, Georgia, developing and commercializing the proprietary Videssa® blood test for breast cancer. Videssa has been clinically validated for the early and accurate detection of breast cancer based on data from over one thousand patient samples.

“The Videssa technology platform and the menu of cancer and autoantibodies tests from Provista Diagnostics represent a robust, reliable, cost- effective and clinically useful line of products for the early and accurate detection of breast cancer,” said Dr. Jorge Leon, Senior Medical Advisor of Todos. “Once confirmed through a clinical utility study to support reimbursement in breast cancer and bench marking, this pipeline of tests can play a real role in the management of cancer patients worldwide.”

“We are excited to be joining forces with Todos Medical and leveraging the combined knowledge and capabilities of our respective technologies to advance the early detection of breast cancer and other women’s cancers,” said Uriel E. Kusiatin, CEO, Provista Diagnostics. “Provista’s expertise in conducting rigorous prospective clinical trials; clinical validation and the publication of results in peer reviewed journals; as well as our commercial expertise from piloting commercial efforts with approx. 150 providers, gives us a distinct advantage as we position ourselves as the leaders in the space. I look forward to continuing to work with Todos Medical’s leadership to develop best in class diagnostics.”

Concurrent with this announcement, the Company announced that it has appointed Gerald Commissiong, a US-based executive, as Chief Executive Officer, and that it has appointed Daniel Hirsch, an Israeli-based executive of American descent, as Chief Financial Officer. Mr. Commissiong and Mr. Hirsch have been tasked with effectuating the relocation of Todos from Israel to the US so that the Company can focus its development and commercialization efforts of its proprietary Total Biochemical Infrared Analysis (TBIA) cancer diagnostic platform in the United States. Todos’ former CEO, Dr. Herman Weiss, will remain with the Company as Chairman of the Board.

“I am excited about the opportunity to lead the effort to refocus Todos’ efforts on the US market,” said Gerald Commissiong, Chief Executive Officer of Todos. “The TBIA platform developed in Israel has resulted in a CE Mark for breast cancer tests in Europe, where Orot+ (the operational division of www.orot-luces.com) is currently enrolling patients in a commercial validation study to support the commercial launch of the TM-B1 and TM-B2 blood tests later this year. With the pending acquisition of Provista that will give Todos ownership of a CLIA/CAP certified lab and Videssa that has already been validated and commercialized in the United States, we believe that we are positioning Todos to become the premier breast cancer blood testing company, with the potential to expand that leadership position to all cancers.”

Mr. Commissiong is currently a director and President & CEO of Amarantus Bioscience Holdings, Inc. and is interim-CEO of Breakthrough Diagnostics, Inc., Todos’ joint venture with Amarantus. Mr. Commissiong has been responsible for Amarantus’ strategic transactions, licensing, research collaborations, mergers & acquisitions in therapeutics and diagnostics, as well as fund raising, having raised over of $50 million since inception. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University. Mr. Hirsch has over 25 years of experience with a demonstrated history of working with public companies. Mr. Hirsch has management and business development expertise to go along with a strong background in investor relations.

For Full Release: https://www.globenewswire.com/news-release/2020/01/09/1968392/0/en/Todos-Medical-Enters-into-Exclusive-Option-Agreement-to-Acquire-Provista-Diagnostics-and-Announces-Management-Changes.html

Nov. 14, 2019 - Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, and Amarantus Bioscience Holdings, Inc. a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that their joint venture company, Breakthrough Diagnostics, Inc. has completed enrollment of its ongoing clinical trial evaluating the relationship of Alzheimer’s blood diagnostic Lymphocyte Proliferation Test (LymPro Test™) with amyloid PET neuroimaging at Leipzig University in Germany (the ‘LymPro PET 2’). Topline results are expected before the end of the first quarter of 2020.

Breakthrough completed a 20-subject clinical study (LymPro PET 1) in 2018 evaluating the correlation between LymPro scores and the diagnosis of Alzheimer’s disease, as confirmed with amyloid PET neuroimaging and other Alzheimer’s disease biomarkers. LymPro measures cell cycle dysregulation in peripheral lymphocytes. The top-line data, announced in July 2019, revealed a strong and statistically significant correlation between LymPro scores and amyloid PET neuroimaging cSUVR scores (r = -0.849; p = 0.00000216). Breakthrough’s academic collaborators at the Leipzig University then expanded enrollment of that study to include an additional cohort of 20 subjects (LymPro PET 2) to confirm the strong relationship seen from LymPro PET 1. The data from both LymPro 1 and LymPro 2 will be published together in a peer-reviewed journal in 2020.

“LymPro is a unique immune system-based Alzheimer’s blood test,” said Dr. Herman Weiss, President & CEO of Todos. “LymPro could prove to be a major breakthrough for  Alzheimer’s disease diagnosis by measuring cell cycle dysregulation and amyloid, together, conveniently as part of a blood workup in routine clinical practice. The therapeutic field in Alzheimer’s has begun to see some renewed hope based upon recent Aducanumab data announced by Biogen that is directly related to the amyloid hypothesis, as well as conditional approval by the National Medical Products Administration in China for the first new Alzheimer’s drug in over 20 years, called Oligomannate from Shanghai Green Valley Pharmaceuticals, that is based on gut-brain biology of the microbiome and its effects on the immune system. We believe this renewed optimism and broadening of pathophysiological hypotheses relevant to Alzheimer’s disease being evaluated in the clinic significantly increases the scope for LymPro pharma services collaborations and begins to refine LymPro’s clinical utility profile for primary care physicians as strategies to correct cell cycle dysregulation emerge.”

About Alzheimer’s Disease
According to the Alzheimer’s Association, it is estimated that over 5.4 million people in the United States suffer from Alzheimer’s disease. Over 500,000 patients are diagnosed annually, with nearly one-in-eight older Americans affected by the disease. Alzheimer’s disease is the third leading cause of death in the United States. The cost of unpaid care in the United States is estimated at over $210 billion annually. Total payments for care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. Alzheimer’s expenditures in the United States are expected to exceed $1.2 trillion by 2050. There is no cure or effective treatment for Alzheimer’s disease. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer’s by 2050.

About Dr. Arendt’s Research at Leipzig University
Dr. Thomas Arendt is Professor of Neuroscience at Leipzig University where he runs the Paul Flechsig Institute of Brain Research. He has a 30-year record in R&D of therapeutic and diagnostic strategies of neurodegenerative disorders and made several seminal contributions to therapeutic concepts of Alzheimer’s disease, including stem cell therapy and modulating tumor suppressor genes. In the early 1980’s, he was involved in identifying the degeneration of the cholinergic system in Alzheimer’s disease laying the basis for today’s only available treatment. He is one of the pioneers of the “cell-cycle theory” of Alzheimer’s disease, which he developed towards a diagnostic and therapeutic concept.

About Breakthrough Diagnostics, Inc.
Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) (80.01%) and Todos Medical Ltd. (19.99%). Breakthrough has been assigned the intellectual property and other rights to the LymPro Test®, a diagnostic blood test for Alzheimer’s disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical has provided Amarantus with notice of Todos’ decision to exercise its exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.

The Lymphocyte Proliferation Test (LymPro Test™) determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as surrogates for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

For Full Release: https://www.globenewswire.com/news-release/2019/11/14/1947429/0/en/Todos-and-Amarantus-JV-Announces-Full-Enrollment-for-Clinical-Trial-of-LymPro-Alzheimer-s-Blood-Test-Relationship-with-Amyloid-PET.html

Oct. 24, 2019 - Todos Medical to Present at Dawson James Small Cap Growth Conference

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that Company management will present at the Dawson James Small Cap Growth Conference on Tuesday, October 29, 2019 beginning at 3:15 P.M. Eastern time. The conference will be held October 28-29 at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida.

About Todos Medical Ltd.
Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer’s disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Breakthrough Diagnostics is developing the LymPro Test®, a blood test for diagnosing Alzheimer’s disease.

For Full Release: https://www.globenewswire.com/news-release/2019/10/24/1935052/0/en/Todos-Medical-to-Present-at-Dawson-James-Small-Cap-Growth-Conference.html

Sept. 24, 2019 - Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, and Orot+, the operational division of Orot-Luces (http://orot-luces.com), that executed a distribution agreement with Todos for the commercial distribution of Todos’ TM-B1and TM-B2 blood screening tests for breast cancer, today announced the enrollment of the first patient in the pre-commercial launch study of TM-B1 and TM-B2 in Europe. The pre-commercial launch study is expected to last approximately 6 months. Upon completion of the pre-commercial launch study, TM-B1 and TM-B2 are expected to be available for commercial sale in Romania by Orot. Orot is providing full funding for the pre-commercial launch study as well as the commercial launch in accordance with the terms of the exclusive distribution agreement.

“In accordance with the exclusive distribution agreement for both our TM-B1 and TM-B2 breast cancer screens in Romania and Austria executed in April 2019, Orot has commenced screening of patients as part of the agreed upon pre-sale preparation study required to support commercial launch in Romania. We are excited to achieve this critical milestone along our path to full commercialization in Europe,” said Dr. Herman Weiss, President & CEO of Todos Medical.  “Our blood tests are designed to screen for the presence of breast cancer at early stages of disease, and we know that early diagnosis and treatment greatly improves patient outcomes.”

“The initiation of the pre-commercial study of Todos Medical’s TM-B1 and TM-B2 breast cancer blood screening tests will help create  awareness among the medical community and local patient population of an affordable test that addresses the unmet need for improved breast cancer screening,” said Mr. Ron Streichman, CEO of Orot-Luces. “We have received encouraging feedback from medical practitioners and expect this to continue as they become aware of the significant potential for improved patients outcomes based upon the data generated in this patient population.”

About TM-B1 and TM-B2 Breast Cancer Blood Tests

The Company’s two breast cancer screening tests, TM-B1 and TM-B2, have received CE mark to support commercialization in Europe. In April 2019, the Company entered into an exclusive distribution agreement with Orot+, the operational division of Orot-Luces (http://orot-luces.com), to support the commercial distribution and marketing of TM-B1 and TM-B2 in Romania and Austria. In August 2019, Orot and Todos entered into a memorandum of understanding to expand the territories under the distribution agreement to include Japan.

The TM-B1 assay is indicated for women aged 25 years and older without a diagnosis of inflammatory disease. The assay is intended to be used as a diagnostic method to indicate whether or not a breast malignancy is present. TM-B1 results are initially intended to be used in conjunction with other common diagnostic tests as part of breast cancer screening. In our latest clinical trial, the TM-B1 assay showed a sensitivity of 86% and a specificity of  98%. Positive predictive value was 95.1% and negative predictive value was 93.5%.

The TM-B2 assay is indicated for women who meet the following criteria: Female subjects, aged 25 years and older, without a diagnosis of inflammatory or autoimmune disease and who were diagnosed as presenting with BI-RADS score of 3 or 4 (or equivalent). TM-B2 is to be used to further assess if a malignancy is present or not. TM-B2 results are initially intended to be used in conjunction with other common diagnostic tests as part of breast cancer screening. In our latest clinical trial, the TM-B2 assay showed a sensitivity of 83% and a specificity of 99%.

For Full Release: https://www.globenewswire.com/news-release/2019/09/24/1919996/0/en/Todos-Medical-and-Orot-Announce-First-Patient-Enrolled-in-Pre-Commercial-Launch-Preparations-of-TM-B1-and-TM-B2-Breast-Cancer-Blood-Screening-Tests-in-Europe.html

Sept. 13, 2019 - Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced it has entered into a binding term sheet with HWH World Pte Ltd. (“HWH World”), a wholly-owned subsidiary of Singapore eDevelopment (SGX:40V) for the grant of exclusive marketing rights for Todos Medical’s TM-B1 and TM-B2 tests to HWH World’s network of members in Singapore, Malaysia, the Philippines, Vietnam, Thailand, Indonesia, South Korea, Hong Kong, China, the United States and Canada. HWH World is a marketing firm that focuses on health and wellness. HWH World will work closely with Todos Medical to achieve regulatory approval in Singapore, where Todos Medical recently completed clinical studies, and thereafter expand into other markets. Todos remains free to partner with other companies to market and distribute its diagnostic tests through traditional means, including direct to consumer, through physicians, hospitals and/or government health systems.

“Todos Medical’s innovative artificial intelligence-based blood testing technology has shown strong results for breast cancer screening and diagnosis in Singapore,” said Heng Fai Chan, Chairman of HWH World. “This represents a tremendous opportunity for HWH World members to take control of their healthcare by getting better information about potential cancer to ensure they are seeking treatment early in the disease progression. This will improve the well-being of our female members and help differentiate us from other wellness programs in the market. Many Asian women are forced to have unnecessary breast biopsies because mammograms are not very effective in this population. Todos has identified a solution to this problem, and HWH World is looking forward to bringing the TM-B1 and TM-B2 tests to our members both in Asia and as we expand into North America.”

“Having just completed a substantial clinical study in Singapore that demonstrated the superiority of our assay versus mammography in prospectively classifying cancer and non-cancer subjects, especially among those with inconclusive mammogram results (BI-RADS III/IV), we are pleased to secure our first Asian partner in HWH World.  Our two companies are aligned in viewing the significant value by utilizing a blood test that will determine whether a biopsy is necessary in breast cancer,” said Herman Weiss, M.D., President and CEO of Todos Medical.

For Full Release: https://www.globenewswire.com/news-release/2019/09/13/1915349/0/en/Todos-Medical-Signs-Binding-Term-Sheet-with-HWH-World-for-Network-Marketing-of-Blood-Tests-for-the-Early-Detection-of-Breast-Cancer.html

Sept. 03, 2019 - Todos Medical Enters into MOU to Expand Existing Early Detection Breast Cancer Blood Test Distribution Partnership with Orot+ into Japan

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that the Company  has entered into a non-binding Memorandum of Understanding (MOU) with Orot+,  the operational division of Orot-Luces (http://orot-luces.com), to expand their existing  launch and distribution partnership for the commercial sale of Todos’ early breast cancer detection blood tests TM-B1 and TM-B2 into Japan. 

Under the terms of the MOU, Orot+ has agreed to spend a minimum of $2.5M towards clinical development, regulatory approval and commercial launch of the tests by way of a soon to be formed Japanese Distribution Company which will be granted the exclusive rights to sell and distribute TM-B1 and TM-B2 in Japan. The execution of this MOU expands the relationship between Todos and Orot+, as the companies signed a definitive exclusive distribution agreement for both of TM-B1 and TM-B2 in Romania and Austria in April 2019.

“We are excited to expand our commercialization network for TM-B1 and TM-B2 into Japan, and are especially happy we are again partnering with Orot+, who will drive the market launch and distribution efforts.  Our blood tests are designed to detect the presence of breast cancer at early stages of disease, and we know that early diagnosis and treatment greatly improves patient outcomes,” said Dr. Herman Weiss, President & CEO of Todos Medical.  “Japan, like much of Asia, has an enhanced need for alternatives to mammogram as the primary breast cancer diagnostic, due to the high incidence of women with dense breast tissue, making this an especially important market for us.”

“We are satisfied that Todos has recognized our unique market position and decided to partner with us to launch their cancer detection blood test in the Japanese market. While Japan has the worlds second largest economy, there are serious unmet needs in cancer care. Orot is focused on offering unique and customized diagnostic solutions,” said Mr. Ron Streichman, CEO of Orot-Luces.

For Full Release: https://www.globenewswire.com/news-release/2019/09/03/1910303/0/en/Todos-Medical-Enters-into-MOU-to-Expand-Existing-Early-Detection-Breast-Cancer-Blood-Test-Distribution-Partnership-with-Orot-into-Japan.html

Aug. 06, 2019 - Todos Medical Appoints Dr. Jorge Leon as Medical Advisor

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s disease, today announced the appointment of Jorge Leon, PhD, as a medical advisor to assist the Company in clinical development, regulatory strategy and fund raising. Dr. Leon is an in-vitro diagnostics expert, having served as a key executive in the establishment of what is now known as Quest Diagnostics.

“The importance of early disease detection cannot be overstated, and the earliest signs of disease often appear when looking at the immune system,” said Dr. Leon, newly appointed medical advisor to Todos. “Todos’ cancer and Alzheimer’s platforms have been developed with the specific intention of being able to measure fundamental disease pathology in the immune system at the earliest stages. I am excited to work closely with the team being assembled to help drive clinical and regulatory execution so that these early disease screening platforms can reach their full commercial potential, with an initial focus on early adoption along key constituencies in the US and abroad. The early detection of cancer would dramatically improve patient outcomes, and the early detection of Alzheimer’s disease is the key unmet need to drive research investment towards altering the underlying course of disease progression before it becomes too late to intervene.”

“Dr. Leon’s track record speaks for itself in terms of his accomplishments and contributions to the field of human diagnostics by dramatically improving patient access to cutting edge diagnostics technologies,” said Dr. Herman Weiss, President & CEO of Todos Medical. “We are excited to bring Dr. Leon onto the team at Todos as we are preparing to launch our TBIA cancer platform in Europe and Israel, as well as assisting biopharmaceutical companies in their quest to develop new therapeutics for Alzheimer’s. His expertise and relationships will be instrumental to Todos’ progress as we move forward.”

Dr. Jorge Leon is internationally recognized for his pioneering work in molecular diagnostics. Dr. Leon holds a Ph.D. in cellular and molecular biology from New York University, and completed his postdoctoral studies at the German Cancer Research Center in Heidelberg and Columbia University in NYC. Dr. Leon’s subsequent academic research at Columbia University focused on developing monoclonal antibody-based tumor marker assays and radio-immuno imaging devices, which are currently in wide use. In the early 1990s, Dr. Jorge Leon played an integral role in establishing and leading the molecular diagnostics laboratories at Quest Diagnostics. As Director of Molecular Diagnostics, Senior Director of Biotechnology Development, and Vice President of Applied Genomics, Dr. Leon spent twelve years developing Quest’s molecular diagnostics strategy, which is now the world’s largest molecular diagnostics service laboratory. In 2003, Dr. Leon founded Leomics Associates, Inc. a consulting firm committed to helping prestigious, successful companies and academic institutions develop molecular diagnostics and personalized medicine in the United States and globally. Dr. Jorge Leon and his experienced team specializes in identifying breakthrough opportunities and industry trends, and helps start-up businesses, academic centers and established companies successfully build and commercialize innovative business strategies, product pipelines, and test menus.

For Full Release: https://www.globenewswire.com/news-release/2019/08/06/1897420/0/en/Todos-Medical-Appoints-Dr-Jorge-Leon-as-Medical-Advisor.html

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform.  For todos medical ltd. financial and corporate news dissemination, FinancialBuzz.com has signed a four month agreement with the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has agreed to two and a half million restricted shares, FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.